AZ1

AZ1 (3-[[(2S)-tetrahydrofuran-2-yl]methyl]-2-thioxo-7H-purin-6-one) is a potent, irreversible 2-thioxanthine myeloperoxidase (MPO) inhibitor developed by AstraZeneca. It is being investigated as a potential therapeutic treatment for chronic obstructive pulmonary disease (COPD) by targeting the inflammation and oxidative stress caused by cigarette smoke. In preclinical studies, AZ1 demonstrated the ability to prevent or stop the progression of emphysema, small airway remodeling, and partially protect against pulmonary hypertension, even when treatment was initiated late in the course of smoke exposure. Its protective effects are believed to stem from inhibiting oxidative damage and down-regulating the smoke-induced inflammatory response.

Other names

3-[[(2S)-tetrahydrofuran-2-yl]methyl]-2-thioxo-7H-purin-6-one